Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
27 February 2017
Highlights: Total sales of $34.3m up on prior comparable period on a constant currency basis Ellex iTrack business segment global sales of $3.6m up 37% on prior comparable period on a constant currency basis with acceleration of sales growth in USA since 31 December 2016 EBITDA of $3.2m up on prior comparable period after adjusting for investments in high-growth Ellex iTrack and 2RT for early macular degeneration business segments Approval received from Australian Therapeutic Goods Administration (TGA) on 17 February 2017 of new laser and ultrasound production facility at Mawson Lakes, South Australia Enhanced reporting of the business into three segments; Core Laser and Ultrasound, Ellex iTrack and 2RT for Early AMD provides additional visibility of high growth business segments Adelaide, Australia, 27 February 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today released its financial results fo
2 February 2017
Adelaide, Australia, 2 February 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that its sales revenue for the six months ended 31 December 2016 will be similar to the prior corresponding period (PCP). The primary cause of the lack of sales growth during the last half year period was the shift of management focus to the establishment of Ellex’s new manufacturing facility at Mawson Lakes, Adelaide at the expense of meeting production challenges resulting in production capacity limitations and a consequent inability to deliver core Laser and Ultrasound product against targets. This resulted in a significant customer order backlog as at 31 December 2016, which we expect to deliver against in the half year ending 30 June 2017 as production at Mawson Lakes ramps up. The iTrack product, which is manufactured at Ellex’s Fremont California facility, was unaffected and iTrack sales increased signif
15 December 2016
Adelaide, Australia, 15 December 2016 – Ellex Medical Lasers Limited (ASX: ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that clinical training of physicians in China in the use of the Ellex iTrack™ minimally invasive glaucoma surgery (MIGS) device has commenced. The Ellex iTrack™ is the only MIGS device in the world currently approved by the Chinese medical device regulatory authority for sale in China. First clinical training in ABiC with Ellex iTrack™ This is the first program of clinical training of physicians in the ab interno canaloplasty (ABiC) technique. This program is being conducted at leading hospitals and teaching institutions in Shanghai and Beijing during 12-17 December 2016. “To date, sales in China have been limited because only the more complex ab externo canaloplasty surgery technique has been marketed. Like it has in the USA, our program in China to relaunch Ellex iTrack for the simpler, faster ABiC techniqu
Annual Report 2016
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.